In this present review, we aim to summarize published randomized controlled trials on the efficacy and tolerability of different regimens of adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive early breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.